BIOMARK SELECTED BY the Medical Alley and Investissement Quebec TO JOIN the US Go-to-Market Accelerator
![biomark appoints dr jean francois haince as strategic advisor to guide its expansion into quebec](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-appoints-dr-jean-francois-haince-as-strategic-advisor-to-guide-its-expansion-into-quebec.jpg)
BIOMARK SELECTED BY THE MEDICAL ALLEY AND INVESTISSEMENT QUEBEC TO JOIN THE US GO-TO-MARKET ACCELERATOR Vancouver, British Columbia – (September 1, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic […]
3 Cancer Diagnostic Stocks To Watch Following Roche’s GenMark Buy
![3 cancer diagnostic stocks to watch following roche genmark buy](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/3-cancer-diagnostic-stocks-to-watch-following-roche-genmark-buy.jpg)
Biotech companies are showing leadership in early detection of cancer. March 16, 2021 Melanie Schaffer , Benzinga Staff Writer In January, Exact Sciences Corporation EXAS 1.59% announced it completed its acquisition of Thrive Earlier Detection Corp. and got Thrive’s blood-based multi-cancer detection technology. Why It Matters: Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in […]
Doctors fear an impending wave of cancer patients after COVID-19 delays
![doctors fear an impending wave of cancer patients after covid 19 delays](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/doctors-fear-an-impending-wave-of-cancer-patients-after-covid-19-delays.jpg)
BY MORGAN LOWRIE, THE CANADIAN PRESS Posted Feb 4, 2021 10:24 am PST MONTREAL, Italy — While the prospectof mass vaccination has raised hopes of the COVID-19 crisis soon waning, oncologists and cancer researchers say one of its grim legacies may be a lingering increase in cancer mortality rates. The pandemic caused a “dramatic” drop in […]
BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer
![biomark announces peer reviewed publication on detection of cancer](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-announces-peer-reviewed-publication-on-detection-of-cancer.jpg)
Vancouver, British Columbia – (June 23 , 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer […]
BioMark Diagnostics Forms New Company, Bio Stream Diagnostics Inc., for ‘30-Second’ COVID-19 Screening
![biostream 30 second covid 19 screening](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biostream-30-second-covid-19-screening.jpg)
Rapid COVID-19 testing will use machine learning and advanced Raman spectroscopy to provide low-cost, accurate results Vancouver, British Columbia – (June 10 , 2020) – – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and […]
WHO outlines steps to save 7 million lives from cancer
![who outlines steps to save 7 million lives from cancer](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/who-outlines-steps-to-save-7-million-lives-from-cancer.jpg)
4 February 2020 News release Geneva, Switzerland The World Health Organization (WHO) today spells out the need to step up cancer services in low and middle-income countries. WHO warns that, if current trends continue, the world will see a 60% increase in cancer cases over the next two decades. The greatest increase (an estimated 81%) in new […]
About Glioblastoma (GBM)
![about glioblastoma gbm](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/about-glioblastoma-gbm.jpg)
Overview Tumour Group: Gliomas WHO Grade: Grade IV Prevalence/Incidence: The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours. GBMs increase in frequency with age, and affect […]
Lung Cancer Screening in Real World Has High False-Positive Rate
![lung cancer screening in real world has high false positive rate](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/lung-cancer-screening-in-real-world-has-high-false-positive-rate.jpg)
By Kelly YoungEdited by: David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD A pair of studies in JAMA Internal Medicine illustrate the difficulties of implementing lung cancer screening. In the first, eight Veterans Health Administration medical centers identified and screened patients using low-dose computed tomography (LDCT). Over 2100 patients who were eligible for screening based […]